Exclusive

Publication

Byline

Location

Government Medical College and Hospital, Sector 32, Chandigarh team finds Panchkula school assault accused has ADHD and conduct disorder

India, Nov. 18 -- A three-member team of doctors at Government Medical College and Hospital (GMCH), Sector 32, Chandigarh found that an eight-year-old boy accused of assaulting his six-year-old junior... Read More


Smile Foundation director programme (health) outlines anaemia symptoms, causes and dietary tips

India, Nov. 18 -- Dr Rashmi Ardey, director programme (health) at Smile Foundation, shared details on anaemia, including its symptoms, causes, diagnostic tests and dietary measures, in an informationa... Read More


Hindustan Times reports Dr Ravi Kesri outlines who needs annual health check-ups and what they should include

India, Nov. 18 -- Hindustan Times reported that Dr Ravi Kesri, consultant in internal medicine at Apollo Spectra Hospital, Bengaluru, said the need for regular health assessments varies by age, medica... Read More


World Health Organization data cited in World Cervical Cancer Elimination Day report highlights low screening rates in India

India, Nov. 18 -- A report published on Nov. 17, 2026, marking World Cervical Cancer Elimination Day, cited World Health Organization data stating that 1 in every 5 women suffering from cervical cance... Read More


Hindustan Times reports Dr Pallavi Vasal comments on perimenopause and brain fog

India, Nov. 18 -- Hindustan Times reported that Dr Pallavi Vasal, clinical director of obstetrics and gynaecology at Marengo Asia Hospitals, Gurugram, discussed what she described as a link between pe... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants with Obesity or Overweight who are Otherwise Healthy

Singapore, Nov. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to... Read More


Singapore Clinical Trial: A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)

Singapore, Nov. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Par... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Singapore, Nov. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More


Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Nov. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults with a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)

Singapore, Nov. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More